A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Required: PD-L1 (CD274) expression TC ≥ 1% (TC ≥ 1%)

Provision of acceptable tumor sample to confirm tumor PD-L1 expression TC ≥ 1%.

Cannot have received: systemic therapy

Any prior systemic therapy received for advanced or mNSCLC.

Cannot have received: anti-PD-1 therapy

Any prior treatment with an anti-PD-1 or anti-PD-L1 agent.

Cannot have received: anti-TIGIT therapy

Any prior exposure to an anti-TIGIT therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms.

Cannot have received: anticancer therapy targeting immune-regulatory receptors or mechanisms

Any prior exposure to an anti-TIGIT therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms.